Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716 · View on ClinicalTrials.gov ↗
Study Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Conditions Studied
Interventions
- DRUG BGB-16673
Study Locations (20)
Arizona
- Mayo Clinic Phoenix — Phoenix
- Honor Health Research Institute — Scottsdale
- University of Arizona Cancer Center — Tucson
California
- University of California San Diego (Ucsd) Moores Cancer Center — La Jolla
- Stanford Medicine — Palo Alto
- UCLA Santa Monica Cancer Care — Santa Monica
Florida
- Mayo Clinic Jacksonville — Jacksonville
- Mount Sinai Comprehensive Cancer Center — Miami Beach
- Tampa General Hospital Cancer Institute — Tampa
Georgia
- Augusta University — Augusta
- Southeastern Regional Medical Center — Newnan
Alabama
- University of Alabama At Birmingham Hospital — Birmingham
Colorado
- Uchealth North — Fort Collins
Illinois
- Midwestern Regional Medical Center — Zion
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2029-11 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05006716
The ClinicalTrials.gov registry entry for NCT05006716 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 138 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention — of which BGB-16673 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05006716 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05006716 about?
NCT05006716 is a clinical study titled "A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies". Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
What is the current status of trial NCT05006716?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 614 participants. The study started on 2021-09-13. Estimated completion is 2029-11.
What conditions does trial NCT05006716 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05006716?
The interventions under investigation include: BGB-16673 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05006716?
This trial is sponsored by BeOne Medicines, which has 138 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05006716 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.